Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder
Sponsor: Neuroventi Inc.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, therapeutic exploratory Phase 2 clinical trial designed to evaluate the efficacy and safety of NV01-A02 in pediatric participants diagnosed with Autism Spectrum Disorder (ASD).
Official title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder
Key Details
Gender
All
Age Range
6 Years - 15 Years
Study Type
INTERVENTIONAL
Enrollment
105
Start Date
2025-04-01
Completion Date
2026-12-01
Last Updated
2025-04-30
Healthy Volunteers
No
Conditions
Interventions
Drug: NV01-A02
NV01-A02 will be administered orally at a different dose once daily for 8 weeks. The formulation is a white, film-coated tablet, designed for use in patients with mild to moderate cognitive impairment.
Drug: Placebo (ZP8396)
ZP8396 is a matching placebo tablet administered orally once daily for 8 weeks. The placebo is identical in appearance to NV01-A02 but contains no active ingredient.
Locations (1)
Neuroventi
Seoul, Seoul, South Korea